Omega-3 Polyunsaturated Fatty Acids in Prevention of Mood and Anxiety Disorders

키워드

참고문헌 (100)

1. Collins PY., "Grand challenges in global mental health", Nature, 475, pp.27~30 (2011)
2. Thornicroft G., "Most people with mental illness are not treated", Lancet, 370, pp.807~808 (2007)
3. Han C., "Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?", CNS Drugs, 27(Suppl 1), pp.S47~S51 (2013)
4. Cyril S., "Urbanisation, urbanicity, and health : a systematic review of the reliability and validity of urbanicity scales", BMC Public Health, 13, pp.513~ (2013)
5. Gómez-Pinilla F., "Brain foods : the effects of nutrients on brain function", Nat Rev Neurosci, 9, pp.568~578 (2008)
6. Su KP., "Omega-3 polyunsaturated fatty acids for major depressive disorder", Expert Opin Investig Drugs, 22, pp.1519~1534 (2013)
7. van Elst K., "Food for thought : dietary changes in essential fatty acid ratios and the increase in autism spectrum disorders", Neurosci Biobehav Rev, 45, pp.369~378 (2014)
8. Politi P., "Randomized placebo-controlled trials of omega-3 polyunsaturated fatty acids in psychiatric disorders : a review of the current literature", Curr Drug Discov Technol, 10, pp.245~253 (2013)
9. Mischoulon D., "Omega-3 fatty acids in psychiatry", Psychiatr Clin North Am, 36, pp.15~23 (2013)
10. McNamara RK., "Long-chain omega-3 fatty acid deficiency in mood disorders : rationale for treatment and prevention", Curr Drug Discov Technol, 10, pp.233~244 (2013)
11. Su KP., "The omega-3 fatty acid deficiency syndrome: opportunities for disease prevention", pp.315~336 (2013), Nova Science Pub Inc
12. Lin PY., "A meta-analytic review of polyunsaturated fatty acid compositions in dementia", J Clin Psychiatry, 73, pp.1245~1254 (2012)
13. Su KP., "Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels", Biol Psychiatry, 67, pp.550~557 (2010)
14. Lin PY., "A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression", Biol Psychiatry, 68, pp.140~147 (2010)
15. Su KP., "Omega-3 fatty acids for major depressive disorder during pregnancy : results from a randomized, doubleblind, placebo-controlled trial", J Clin Psychiatry, 69, pp.644~651 (2008)
16. Su KP., "Mind-body interface: the role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression", Asia Pac J Clin Nutr, 17(Suppl 1), pp.151~157 (2008)
17. Lin PY., "A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids", J Clin Psychiatry, 68, pp.1056~1061 (2007)
18. Su KP., "Biological mechanism of antidepressant effect of omega-3 fatty acids : how does fish oil act as a 'mind-body interface'?", Neurosignals, 17, pp.144~152 (2009)
19. Bailey RL., "Why US adults use dietary supplements", JAMA Intern Med, 173, pp.355~361 (2013)
20. Su KP., "Inflammation in psychopathology of depression : clinical, biological, and therapeutic implications", Bio-Medicine, 2, pp.68~74 (2012)
21. Lu DY., "Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia : implications of antidepressant effects for ω-3 fatty acids", Neuropsychopharmacology, 35, pp.2238~2248 (2010)
22. Solis M., "Prevention : Before the break", Nature, 508, pp.S12~S13 (2014)
23. Kris-Etherton PM., "Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease", Circulation, 106, pp.2747~2757 (2002)
24. Maes M., "(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression : from antioxidants to kinase inhibitors", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.659~663 (2011)
25. Hibbeln JR., "Fish consumption and major depression", Lancet, 351, pp.1213~ (1998)
26. Hibbeln JR., "Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity", Am J Clin Nutr, 83(6 Suppl), pp.1483S~1493S (2006)
27. Noaghiul S., "Cross-national comparisons of seafood consumption and rates of bipolar disorders", Am J Psychiatry, 160, pp.2222~2227 (2003)
28. McNamara RK., "Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder", Biol Psychiatry, 62, pp.17~24 (2007)
29. Hamazaki K., "Abnormalities in the fatty acid composition of the postmortem entorhinal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder", Psychiatry Res, 210, pp.346~350 (2013)
30. Hamazaki K., "Fatty acid composition in the postmortem amygdala of patients with schizophrenia, bipolar disorder, and major depressive disorder", J Psychiatr Res, 46, pp.1024~1028 (2012)
31. De Vriese SR., "Lowered serum n-3 polyunsaturated fatty acid(PUFA)levels predict the occurrence of postpartum depression : further evidence that lowered n-PUFAs are related to major depression", Life Sci, 73, pp.3181~3187 (2003)
32. Green P., "Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder", Eur Neuropsychopharmacol, 16, pp.107~113 (2006)
33. Tiemeier H., "Plasma fatty acid composition and depression are associated in the elderly : the Rotterdam Study", Am J Clin Nutr, 78, pp.40~46 (2003)
34. Frasure-Smith N., "Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes", Biol Psychiatry, 55, pp.891~896 (2004)
35. Chiu CC., "Polyunsaturated fatty acid deficit in patients with bipolar mania", Eur Neuropsychopharmacol, 13, pp.99~103 (2003)
36. McNamara RK., "Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder", J Affect Disord, 126, pp.303~311 (2010)
37. Ranjekar PK., "Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients", Psychiatry Res, 121, pp.109~122 (2003)
38. Sublette ME., "Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania", Bipolar Disord, 9, pp.759~765 (2007)
39. Clayton EH., "Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder", Lipids, 43, pp.1031~1038 (2008)
40. Sobczak S., "Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients", Psychol Med, 34, pp.103~112 (2004)
41. Stoll AL., "Omega 3 fatty acids in bipolar disorder : a preliminary double-blind, placebo-controlled trial", Arch Gen Psychiatry, 56, pp.407~412 (1999)
42. Su KP., "Are omega3 fatty acids beneficial in depression but not mania?", Arch Gen Psychiatry, 57, pp.716~717 (2000)
43. Osher Y., "Omega-3 eicosapentaenoic acid in bipolar depression : report of a small open-label study", J Clin Psychiatry, 66, pp.726~729 (2005)
44. Sagduyu K., "Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study", Nutr J, 4, pp.6~ (2005)
45. Frangou S., "Efficacy of ethyl-eicosapentaenoic acid in bipolar depression : randomised doubleblind placebo-controlled study", Br J Psychiatry, 188, pp.46~50 (2006)
46. Clayton EH., "Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation", Eur J Clin Nutr, 63, pp.1037~1040 (2009)
47. Frangou S., "Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder", J Psychopharmacol, 21, pp.435~439 (2007)
48. Keck PE Jr., "Double-blind, randomized, placebocontrolled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder", Biol Psychiatry, 60, pp.1020~1022 (2006)
49. Gracious BL., "Randomized, placebocontrolled trial of flax oil in pediatric bipolar disorder", Bipolar Disord, 12, pp.142~154 (2010)
50. Freeman MP., "Complementary and alternative medicine for major depressive disorder : a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants", J Clin Psychiatry, 71, pp.682~688 (2010)
51. Sublette ME., "Meta-analysis of the effects of eicosapentaenoic acid(EPA)in clinical trials in depression", J Clin Psychiatry, 72, pp.1577~1584 (2011)
52. Martins JG., "Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder : a critique of Bloch and Hannestad and updated metaanalysis", Mol Psychiatry, 17, pp.1144~1149 (2012)
53. Lin PY., "Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression", Mol Psychiatry, 17, pp.1161~1163 (2012)
54. Mischoulon D., "A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder", J Clin Psychiatry, 70, pp.1636~1644 (2009)
55. Mischoulon D., "A double-blind dose-finding pilot study of docosahexaenoic acid(DHA)for major depressive disorder", Eur Neuropsychopharmacol, 18, pp.639~645 (2008)
56. Nemets H., "Omega-3 treatment of childhood depression : a controlled, double-blind pilot study", Am J Psychiatry, 163, pp.1098~1100 (2006)
57. Peet M., "A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs", Arch Gen Psychiatry, 59, pp.913~919 (2002)
58. Nemets B., "Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder", Am J Psychiatry, 159, pp.477~479 (2002)
59. Su KP., "Omega-3 fatty acids in major depressive disorder. A preliminary doubleblind, placebo-controlled trial", Eur Neuropsychopharmacol, 13, pp.267~271 (2003)
60. Sinn N., "Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment : a 6-month randomised controlled trial", Br J Nutr, 107, pp.1682~1693 (2012)
61. Jazayeri S., "Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder", Aust N Z J Psychiatry, 42, pp.192~198 (2008)
62. Appleton KM., "Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood", Am J Clin Nutr, 91, pp.757~770 (2010)
63. Rogers PJ., "No effect of n-3 long-chain polyunsaturated fatty acid(EPA and DHA)supplementation on depressed mood and cognitive function : a randomised controlled trial", Br J Nutr, 99, pp.421~431 (2008)
64. Bloch MH., "Omega-3 fatty acids for the treatment of depression : systematic review and meta-analysis", Mol Psychiatry, 17, pp.1272~1282 (2012)
65. Richardson AJ., "n-3 Fatty acids and mood : the devil is in the detail", Br J Nutr, 99, pp.221~223 (2008)
66. Carlezon WA Jr., "Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats", Biol Psychiatry, 57, pp.343~350 (2005)
67. Huang SY., "Omega-3 fatty acids on the forced-swimming test", J Psychiatr Res, 42, pp.58~63 (2008)
68. Song C., "Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression : effects of chronic ethyl-eicosapentaenoate treatment", J Neurosci, 29, pp.14~22 (2009)
69. Lakhwani L., "Omega-3 fatty acids have antidepressant activity in forced swimming test in Wistar rats", Acta Pol Pharm, 64, pp.271~276 (2007)
70. Lu DY., "Interferon-α induces nitric oxide synthase expression and haem oxygenase-1 downregulation in microglia : implications of cellular mechanism of IFN-α-induced depression", Int J Neuropsychopharmacol, 16, pp.433~444 (2013)
71. Berton O., "New approaches to antidepressant drug discovery : beyond monoamines", Nat Rev Neurosci, 7, pp.137~151 (2006)
72. Fournier JC., "Antidepressant drug effects and depression severity : a patient-level meta-analysis", JAMA, 303, pp.47~53 (2010)
73. Su KP., "Omega-3 fatty acids in the prevention of interferonalpha-induced depression : results from a randomized, controlled trial", Biol Psychiatry, 76, pp.559~566 (2014)
74. Dalton SO., "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding : a population-based cohort study", Arch Intern Med, 163, pp.59~64 (2003)
75. Gleason OC., "Plasma levels of citalopram in depressed patients with hepatitis C", Psychosomatics, 45, pp.29~33 (2004)
76. Hejny C., "Retinopathy associated with high-dose interferon alfa-2b therapy", Am J Ophthalmol, 131, pp.782~787 (2001)
77. Musselman DL., "Paroxetine for the prevention of depression induced by high-dose interferon alfa", N Engl J Med, 344, pp.961~966 (2001)
78. Morasco BJ., "A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C", J Affect Disord, 103, pp.83~90 (2007)
79. Wu PL., "Manic episode associated with citalopram therapy for interferoninduced depression in a patient with chronic hepatitis C infection", Gen Hosp Psychiatry, 29, pp.374~376 (2007)
80. Song C., "Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens : involved with PLA2 activity and corticosterone secretion", Neuropsychopharmacology, 32, pp.736~744 (2007)
81. Song C., "Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats", J Lipid Res, 44, pp.1984~1991 (2003)
82. Fux M., "A placebo-controlled cross-over trial of adjunctive EPA in OCD", J Psychiatr Res, 38, pp.323~325 (2004)
83. Zeev K., "Possible deleterious effects of adjunctive omega-3 fatty acids in post-traumatic stress disorder patients", Neuropsychiatr Dis Treat, 1, pp.187~190 (2005)
84. Buydens-Branchey L., "Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.568~575 (2008)
85. Haberka M., "Effects of n-3 polyunsaturated fatty acids on depressive symptoms, anxiety and emotional state in patients with acute myocardial infarction", Pharmacol Rep, 65, pp.59~68 (2013)
86. Kiecolt-Glaser JK., "Omega-3 supplementation lowers inflammation and anxiety in medical students : a randomized controlled trial", Brain Behav Immun, 25, pp.1725~1734 (2011)
87. Matsuoka Y., "Omega-3 fatty acids for secondary prevention of posttraumatic stress disorder after accidental injury : an open-label pilot study", J Clin Psychopharmacol, 30, pp.217~219 (2010)
88. Nishi D., "Fish oil for attenuating posttraumatic stress symptoms among rescue workers after the great east Japan earthquake : a randomized controlled trial", Psychother Psychosom, 81, pp.315~317 (2012)
89. Delion S., "Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats", J Nutr, 124, pp.2466~2476 (1994)
90. Chalon S., "Polyunsaturated fatty acids and cerebral function : focus on monoaminergic neurotransmission", Lipids, 36, pp.937~944 (2001)
91. Berg KA., "5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism", Mol Pharmacol, 50, pp.1017~1023 (1996)
92. Maes M., "Psychopharmacology, the Fourth Generation of Progress", pp.933~941 (1995), Raven Press
93. Nizzo MC., "Brain cortex phospholipids liposomes effects on CSF HVA, 5-HIAA and on prolactin and somatotropin secretion in man", J Neural Transm, 43, pp.93~102 (1978)
94. Duman RS., "Neural plasticity to stress and antidepressant treatment", Biol Psychiatry, 46, pp.1181~1191 (1999)
95. Santarelli L., "Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants", Science, 301, pp.805~809 (2003)
96. Beltz BS., "Omega-3 fatty acids upregulate adult neurogenesis", Neurosci Lett, 415, pp.154~158 (2007)
97. Kawakita E., "Docosahexaenoic acid promotes neurogenesis in vitro and in vivo", Neuroscience, 139, pp.991~997 (2006)
98. Blondeau N., "Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect : a versatile potential therapy for stroke", Neuropsychopharmacology, 34, pp.2548~2559 (2009)
99. Venna VR., "PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus", Psychoneuroendocrinology, 34, pp.199~211 (2009)
100. Wu A., "Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats", J Neurotrauma, 21, pp.1457~1467 (2004)

관련 논문AI추천